Thinly traded nano cap Interpace Biosciences (NASDAQ:IDXG) perks up 6% premarket on light volume in reaction to its announcement that Medicare has upped its reimbursement for ThyraMIR miRNA classifier from ~$1,800 to $3,000.
Medicare beneficiaries account for ~30% of ThyraMIR test volume
https://seekingalpha.com/news/3540467-interpace-bio-up-6-on-improved-reimbursement-for-thyramir
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.